Drug Trial Radar · NCT07083960
OM336 in Autoimmune Cytopenias
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Dec 2026
Study completion Sep 2027
Sponsor
- Lead sponsor
- Lakefront Biotherapeutics West LLCIndustry
- Sponsor type
- Industry
- First posted
- Jul 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Conditions
- AIHA - Warm Autoimmune Hemolytic Anemia
- AIHA - Cold Autoimmune Hemolytic Anemia
- ITP - Immune Thrombocytopenia
Interventions
OM336Drug
OM336 is an engineered bispecific antibody directed against BCMA and CD3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 12 weeks
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
Medstar
Washington D.C., District of Columbia · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
The Canberra Hospital
Canberra, Australian Capital Territory, Australia · Recruiting
Liverpool Hospital
Sydney, New South Wales, Australia · Recruiting
Icon Cancer Center South Brisbane
Brisbane, Queensland, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.